WO2006086992A3 - Drug delivery systems containing phqspholipase a2 degradable lipid prodrug derivatives and the therapeutic uses thereof as. e.g. wound healing agents and peroxisome proliferator activated receptor ligands - Google Patents

Drug delivery systems containing phqspholipase a2 degradable lipid prodrug derivatives and the therapeutic uses thereof as. e.g. wound healing agents and peroxisome proliferator activated receptor ligands Download PDF

Info

Publication number
WO2006086992A3
WO2006086992A3 PCT/DK2006/000097 DK2006000097W WO2006086992A3 WO 2006086992 A3 WO2006086992 A3 WO 2006086992A3 DK 2006000097 W DK2006000097 W DK 2006000097W WO 2006086992 A3 WO2006086992 A3 WO 2006086992A3
Authority
WO
WIPO (PCT)
Prior art keywords
wound healing
drug delivery
delivery systems
phqspholipase
therapeutic uses
Prior art date
Application number
PCT/DK2006/000097
Other languages
French (fr)
Other versions
WO2006086992A2 (en
Inventor
Kent Joergensen
S Jensen Simon
Thomas L Andresen
Original Assignee
Liplasome Pharma As
Kent Joergensen
S Jensen Simon
Thomas L Andresen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liplasome Pharma As, Kent Joergensen, S Jensen Simon, Thomas L Andresen filed Critical Liplasome Pharma As
Publication of WO2006086992A2 publication Critical patent/WO2006086992A2/en
Publication of WO2006086992A3 publication Critical patent/WO2006086992A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention describes a lipid based prodrug and drug delivery system that can be used for treatment or alleviation of disorders that are associated with or resulting from increased levels of secretory phospholipase A2 (PLA2) in the diseased or injured tissue. In particular, the lipid based delivery systems are useful for administration of lipid prodrugs of lysophosphatidic acid (LPA) bioactive analogs, which are known to be potent biological mediators with e.g. growth stimulating and wound healing activities.
PCT/DK2006/000097 2005-02-18 2006-02-17 Drug delivery systems containing phqspholipase a2 degradable lipid prodrug derivatives and the therapeutic uses thereof as. e.g. wound healing agents and peroxisome proliferator activated receptor ligands WO2006086992A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200500255 2005-02-18
DKPA200500255 2005-02-18

Publications (2)

Publication Number Publication Date
WO2006086992A2 WO2006086992A2 (en) 2006-08-24
WO2006086992A3 true WO2006086992A3 (en) 2007-03-01

Family

ID=36916811

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2006/000097 WO2006086992A2 (en) 2005-02-18 2006-02-17 Drug delivery systems containing phqspholipase a2 degradable lipid prodrug derivatives and the therapeutic uses thereof as. e.g. wound healing agents and peroxisome proliferator activated receptor ligands

Country Status (1)

Country Link
WO (1) WO2006086992A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105434354A (en) * 2009-06-03 2016-03-30 斯昆申技术控股有限责任公司 Formulations for the treatment of deep tissue pain
JP2013502436A (en) 2009-08-21 2013-01-24 ターゲッティド デリバリー テクノロジーズ リミテッド Vesicular preparation
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
CA2946275A1 (en) * 2014-04-04 2015-10-08 Osaka University Drug delivery enhancer comprising substance for activating lysophospholipid receptors
WO2017001625A1 (en) 2015-06-30 2017-01-05 Sequessome Technology Holdings Limited Multiphasic compositions

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986000309A1 (en) * 1984-06-21 1986-01-16 Health Research Inc. Thiophospholipid conjugates of antitumor agents
WO1999065466A1 (en) * 1998-06-18 1999-12-23 Duke University Temperature-sensitive liposomal formulation
US6165501A (en) * 1995-12-11 2000-12-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiation-protective phospholipid and method
WO2001058910A2 (en) * 2000-02-10 2001-08-16 Liplasome Pharma A/S Lipid-based drug delivery systems
US20030170297A1 (en) * 2000-04-12 2003-09-11 Kent Jorgensen Lipid-based drug delivery systems containing phospholipase a2 degradable lipid derivatives for topical application to the skin
WO2004000854A1 (en) * 2002-06-20 2003-12-31 Ic Vec Limited Sulfur-containing phospholipid derivatives

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986000309A1 (en) * 1984-06-21 1986-01-16 Health Research Inc. Thiophospholipid conjugates of antitumor agents
US6165501A (en) * 1995-12-11 2000-12-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiation-protective phospholipid and method
WO1999065466A1 (en) * 1998-06-18 1999-12-23 Duke University Temperature-sensitive liposomal formulation
WO2001058910A2 (en) * 2000-02-10 2001-08-16 Liplasome Pharma A/S Lipid-based drug delivery systems
US20030170297A1 (en) * 2000-04-12 2003-09-11 Kent Jorgensen Lipid-based drug delivery systems containing phospholipase a2 degradable lipid derivatives for topical application to the skin
WO2004000854A1 (en) * 2002-06-20 2003-12-31 Ic Vec Limited Sulfur-containing phospholipid derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HRISTOVA ET AL: "Effect of bilayer composition on the phase behavior of liposomal suspensions containing poly(ethylene glycol) lipids", MACROMOLECULES, ACS, WASHINGTON, DC, US, vol. 28, 1995, pages 7693 - 7699, XP002120858, ISSN: 0024-9297 *
JORGENSEN KENT ET AL: "Interaction of a lipid-membrane destabilizing enzyme with PEG-liposomes", INTERNATIONAL JOURNAL OF PHARMACEUTICS (AMSTERDAM), vol. 183, no. 1, 10 June 1999 (1999-06-10), pages 21 - 24, XP002404579, ISSN: 0378-5173 *

Also Published As

Publication number Publication date
WO2006086992A2 (en) 2006-08-24

Similar Documents

Publication Publication Date Title
WO2007084247A3 (en) Stable therapeutic formulations
BRPI0707235B8 (en) sublingual fentanyl formulation without propellant, and, unit dose device for sublingual administration of a sublingual fentanyl formulation
EP2963031A3 (en) Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same
SG11201808167VA (en) Prodrugs of cytotoxic active agents having enzymatically cleavable groups
WO2011127064A3 (en) Sustained-release reservoir implants for intracameral drug delivery
WO2008079404A3 (en) Pharmaceutical compositions for treatment of parkinson's disease and related disorders
NZ591810A (en) Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid
EA200970287A1 (en) METHODS, COMPOUNDS, COMPOSITIONS AND MEDIA SUITABLE FOR DELIVERY OF 3-AMINO-1-PROPANSULPHONE ACID
NO20084199L (en) Modified release formulations and methods for treating inflammatory bowel disease
WO2006048017A8 (en) Lipid-based drug delivery systems containing unnatural phospholipase a2 degradable lipid derivatives and the therapeutic uses thereof
UY28837A1 (en) OXADIAZOLONAS PROCEDURES FOR PREPARATION AND USE AS PHARMACEUTICAL PRODUCTS.
MX2009004561A (en) Pyrazolyl derivatives with analgesic activity and therefore useful in the treatment or prophylaxis of pain.
EP2386299A3 (en) 1-Amino-Alkylcyclohexane derivatives for the treatment of cochlear tinnitus
WO2010093925A3 (en) Peripheral administration of proteins including tgf-beta superfamily members for systemic treatment of disorders and disease
EP4218823A3 (en) Novel polymeric hgh prodrugs
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
WO2006086992A3 (en) Drug delivery systems containing phqspholipase a2 degradable lipid prodrug derivatives and the therapeutic uses thereof as. e.g. wound healing agents and peroxisome proliferator activated receptor ligands
HK1110221A1 (en) Use of prodrugs for ocular intravitreous administration
MX2012009079A (en) Extended release formulations of rasagiline and uses thereof.
TW200731975A (en) Novel combinations of medicaments for the treatment of respiratory diseases
BRPI0417932A (en) fat accumulation drug lipolysis
WO2011151722A3 (en) Methods and compositions for oral pharmaceutical therapy
UY28209A1 (en) DERIVATIVES OF AMINO ACIDS WITH CYCLLOQUAL, PROCEDURE FOR PREPARATION AND USE AS A MEDICINAL PRODUCT.
WO2001058910A3 (en) Lipid-based drug delivery systems
WO2007124358A3 (en) Pharmaceutical formulations for iontophoretic drug delivery

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06706068

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06706068

Country of ref document: EP

Kind code of ref document: A2

WWW Wipo information: withdrawn in national office

Ref document number: 6706068

Country of ref document: EP